ArticleBrain : a journal of neurology2018
Potentiating tangle formation reduces acute toxicity of soluble tau species in the rat.
Article in Brain : a journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- Chronic cerebral hypoperfusion exacerbates amyloid and tau pathology by impairing glymphatic transport via AQP4- and VEGF-mediated pathways: insights from a vascular to mixed-type dementia model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Soluble and plaque amyloid associations with peripheral glucose dysregulation modulated by tau pathology in Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Observational
- Article
- Rational Modulation of Liquid-Liquid Phase Separation Offers Novel Ways to Combat Tauopathies.International journal of molecular sciences · 2025Review
- Divergent disruptive effects of soluble recombinant tau assemblies on synaptic plasticity in vivo.Molecular brain · 2025Article
- Hyperphosphorylated Tau Inflicts Intracellular Stress Responses that Are Mitigated by Apomorphine.Molecular neurobiology · 2024Article
- Hippocampal hyperphosphorylated tau-induced deficiency is rescued by L-type calcium channel blockade.Brain communications · 2024Article
- Neural atrophy produced by AAV tau injections into hippocampus and anterior cortex of middle-aged mice.Neurobiology of aging · 2023Article
- Probiotic supplement as a promising strategy in early tau pathology prevention: Focusing on GSK-3β?Frontiers in neuroscience · 2023Review
- FX5, a non-steroidal glucocorticoid receptor antagonist, ameliorates diabetic cognitive impairment in mice.Acta pharmacologica Sinica · 2022Article
- Pathological changes induced by Alzheimer's brain inoculation in amyloid-beta plaque-bearing mice.Acta neuropathologica communications · 2022Article
- Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Amyloid and Tau Induce Cell Death Independently of TSPO Polymerization and Density Changes.ACS omega · 2021Article
- A Single Cisterna Magna Injection of AAV Leads to Binaural Transduction in Mice.Frontiers in cell and developmental biology · 2021Article
- The role of wild-type tau in Alzheimer's disease and related tauopathies.Journal of life sciences (Westlake Village, Calif.) · 2020Article
- Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease.ACS chemical neuroscience · 2020Article
- Tau Protein as a New Regulator of Cellular Prion Protein Transcription.Molecular neurobiology · 2020Article
- The Cell Biology of Tau Secretion.Frontiers in molecular neuroscience · 2020Review
- A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.Acta neuropathologica communications · 2019Article
- BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through ThrActa neuropathologica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tauopathies are neurodegenerative diseases characterized by the aggregation of tau protein. These pathologies exhibit a wide variety of clinical and anatomo-pathological presentations, which may result from different pathological mechanisms. Although tau inclusions are a common feature in all these diseases, recent evidence instead implicates small oligomeric aggregates as drivers of tau-induced toxicity. Hence in vivo model systems displaying either soluble or fibrillary forms of wild-type or mutant tau are needed to better identify their respective pathological pathways. Here we used adeno-associated viruses to mediate gene transfer of human tau to the rat brain to develop models of pure tauopathies. Two different constructs were used, each giving rise to a specific phenotype developing in less than 3 months. First, hTAUWT overexpression led to a strong hyperphosphorylation of the protein, which was associated with neurotoxicity in the absence of any significant aggregation. In sharp contrast, its co-expression with the pro-aggregation peptide TauRD-ΔK280 in the hTAUProAggr group strongly promoted its aggregation into Gallyas-positive neurofibrillary tangles, while preserving neuronal survival. Our results support the hypothesis that soluble tau species are key players of tau-induced neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.